Manifestaciones dermatológicas en pacientes con enfermedad inflamatoria intestinal
DOI:
https://doi.org/10.47892/rgp.2026.461.2223Palabras clave:
Enfermedad de Crohn, Colitis Ulcerosa, Enfermedades Inflamatorias del Intestino, Terapéutica, Manifestaciones Cutáneas, Efectos Colaterales y Reacciones Adversas Relacionados con MedicamentosResumen
Las manifestaciones extraintestinales de la enfermedad inflamatoria intestinal son comunes. Estas pueden manifestarse antes del diagnóstico de la patología intestinal y pueden seguir un curso concomitante a su actividad. Por otro lado, el uso de terapias avanzadas e inmunosupresores conlleva, eventualmente, complicaciones adicionales en estos pacientes. Entre las manifestaciones dermatológicas se puede encontrar el pioderma gangrenoso, eritema nodoso, síndrome de Sweet, lesiones aftosas, hidradenitis supurativa, vasculitis, síndrome similar a lupus eritematoso, infecciones, malignidad cutánea, erupciones psoriasiformes y eccematosas. El reconocimiento temprano de estas manifestaciones es fundamental para establecer una estrategia terapéutica efectiva para la enfermedad inflamatoria intestinal y el componente dermatológico, impactando en la evolución natural de las enfermedades. El objetivo de este artículo es brindar una revisión de la literatura actualizada sobre la epidemiología, patogenia, diagnóstico, abordaje terapéutico y pronóstico de las entidades más frecuentes asociadas a la enfermedad inflamatoria intestinal.
Descargas
Citas
Vavricka SR, Galván JA, Dawson H, Soltermann A, Biedermann L, Scharl M, et al. Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. J Crohns Colitis. 2018;12(3):347-354. doi: 10.1093/ecco-jcc/jjx158.
Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21(8):1982-92. doi: 10.1097/MIB.0000000000000392.
Greuter T, Navarini A, Vavricka SR. Skin Manifestations of Inflammatory Bowel Disease. Clin Rev Allergy Immunol. 2017;53(3):413-427. doi: 10.1007/s12016-017-8617-4.
Gordon H, Burisch J, Ellul P, Karmiris K, Katsanos K, Allocca M, et al. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2024;18(1):1-37. doi: 10.1093/ecco-jcc/jjad108.
Chavez-Álvarez S, Gómez-Flores M, Ocampo-Candiani J. Manifestaciones cutáneas en enfermedad inflamatoria intestinal. Gac Med Mex. 2016;152(5):622-630.
Card TR, Langan SM, Chu TP. Extra-Gastrointestinal Manifestations of Inflammatory Bowel Disease May Be Less Common Than Previously Reported. Dig Dis Sci. 2016;61(9):2619-26. doi: 10.1007/s10620-016-4195-1.
Hindryckx P, Novak G, Costanzo A, Danese S. Disease-related and drug-induced skin manifestations in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2017;11(3):203- 214. doi: 10.1080/17474124.2017.1283985.
Iida T, Hida T, Matsuura M, Uhara H, Nakase H. Current clinical issue of skin lesions in patients with inflammatory bowel disease. Clin J Gastroenterol. 2019;12(6):501-510. doi: 10.1007/s12328-019-00958-y.
Varas P, Antúnez-Lay A, Bernucci JM, Cossio L, González S, Eymin G. Eritema nodoso: Causas más prevalentes en pacientes que se hospitalizan para estudio, y recomendaciones para el diagnóstico. Rev Med Chil. 2016;144(2):162-8. doi: 10.4067/ S0034-98872016000200003.
Colìa R, Corrado A, Cantatore FP. Rheumatologic and extraintestinal manifestations of inflammatory bowel diseases. Ann Med. 2016;48(8):577-585. doi: 10.1080/07853890.2016.1195011.
Goldberg I, Finkel O, Gat A, Sprecher E, de Morentin HM. Concomitant occurrence of pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease. Isr Med Assoc J. 2014;16(3):168-70.
Fuentes-Valenzuela E, Chivato Martín-Falquina I, CaballeroMateos AM, Botella Mateu B, Fernández-Prada S, Calvo Moya M, et al. Effectiveness of upadacitinib in patients with baseline active extraintestinal manifestations and inflammatory bowel disease: a multicenter retrospective study. J Crohns Colitis. 2025;19(Suppl 1):i1862–i1864. doi: 10.1093/ecco-jcc/jjae190.1180.
Sanín-Guana A, Lebwohl MG. Ustekinumab in the treatment of erythema nodosum with underlying Crohn’s disease: a case report. J Cutan Med Surg. 2022;6(2):149-151.
da Silva SF. Dermatology Atlas [Internet]. 2011 [citado 7 jun 2025]. Disponible en: https://www.atlasdermatologico.com. br/index.jsf
Diotallevi F, Campanati A, Radi G, Brisigotti V, Molinelli E, Brancorsini D, et al. Pyoderma gangrenosum successfully treated with golimumab: Case report and review of the literature. Dermatol Ther. 2019;32(4):e12928. doi: 10.1111/dth.12928.
Motta I, Perricone G. Ulcerative pyoderma gangrenosum in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2019;4(6):488. doi: 10.1016/S2468-1253(19)30038-X.
Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al. Fitzpatrick’s Dermatology. 9th edition. New York, N.Y: McGraw-Hill Education LLC.; 2019.
Jiang YY, Li J, Li Y, Wang Q, Liu S, Fang K, et al. Comparison of Clinical Features between Pyoderma Gangrenosum Concomitant by Inflammatory Bowel Disease and Idiopathic Pyoderma Gangrenosum. Chin Med J (Engl). 2017;130(22):2674-2679. doi: 10.4103/0366-6999.218004.
Ampuero J, Rojas-Feria M, Castro-Fernández M, Cano C, Romero-Gómez M. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease. J Gastroenterol Hepatol. 2014;29(2):291-5. doi: 10.1111/ jgh.12352.
Yamamoto T, Yamasaki K, Yamanaka K, Komine M, Kawakami T, Yamamoto O, et al. Clinical guidance of pyoderma gangrenosum 2022. J Dermatol. 2023;50(9):e253-e275. doi: 10.1111/1346-8138.16845.
Argüelles-Arias F, Castro-Laria L, Lobatón T, Aguas-Peris M, Rojas-Feria M, Barreiro-de Acosta M, et al. Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease. Dig Dis Sci. 2013;58(10):2949-54. doi: 10.1007/ s10620-013-2762-2.
Shahid S, Myszor M, De Silva A. Pyoderma gangrenosum as a first presentation of inflammatory bowel disease. BMJ Case Rep. 2014;2014:bcr2014204853. doi: 10.1136/bcr-2014-204853.
Sullivan SN. Bullous Pyoderma Gangrenosum and Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018;24(5):e16-e17. doi: 10.1093/ibd/izy018.
Arivarasan K, Bhardwaj V, Sud S, Sachdeva S, Puri AS. Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis. Intest Res. 2016;14(4):365-368. doi: 10.5217/ ir.2016.14.4.365.
Guillo L, D’Amico F, Danese S, Peyrin-Biroulet L. Ustekinumab for Extra-intestinal Manifestations of Inflammatory Bowel Disease: A Systematic Literature Review. J Crohns Colitis. 2021;15(7):1236-1243. doi: 10.1093/ecco-jcc/jjaa260.
Hermak S, Yaghi M, Lev-Tov H. IL-23 inhibitors as a treatment option for pyoderma gangrenosum: a systematic review. J Am Acad Dermatol. 2024;91(3 Suppl):AB51. doi: 10.1016/j. jaad.2024.07.210.
Afifi L, Sanchez IM, Wallace MM, Braswell SF, Ortega-Loayza AG, Shinkai K. Diagnosis and management of peristomal pyoderma gangrenosum: A systematic review. J Am Acad Dermatol 2018;78:1195-1204. doi: 10.1016/j.jaad.2017.12.049.
Taheri A, Mansoori P, Sharif M. Wound Debridement in Pyoderma Gangrenosum. Adv Skin Wound Care. 2024;37(2):107-111. doi: 10.1097/ASW.0000000000000092.
Moore AM, Karch JL, Bradley KE, Stevanovic M, Salem I, Parker DJ, et al. The utility of biopsy in pyoderma gangrenosum: a retrospective cohort study. Skin Health Dis. 2026;:vzaf087. doi: 10.1093/skinhd/vzaf087.
Comonfort‑Palacios TV, Landeta‑Sa AP, Jaramillo‑Manzur SC, Díaz‑Molina VL, Escandón‑Pérez S, Moreno López LM, et al. Pioderma gangrenoso ampolloso diseminado. Dermatol Rev Mex. 2022;66(2):237-44. doi: 10.24245/dermatolrevmex. v66i2.7628.
Diepgen TL, Yihune G, et al. Atlas Dermatológico Online [Internet]. 2025 [citado 7 jun 2025]. Disponible en: https:// www.dermis.net
Skok P, Skok K. Acute febrile neutrophilic dermatosis in a patient with Crohn’s disease: case report and review of the literature. Acta Dermatovenerol Alp Pannonica Adriat. 2018;27(3):161-163.
Madabhushi S, Dixon S, Dong M, Lewandrowski N, Elaba Z, St John J, et al. A case of Sweet syndrome complicating ulcerative colitis treated with upadacitinib. ACG Case Rep J. 2025;12(11):e01904. doi: 10.14309/crj.0000000000001904.
Starita-Fajardo G, Lucena-López D, Ballester-Martínez MA, Fernández-Guarino M, González-García A. Treatment strategies in neutrophilic dermatoses: a comprehensive review. Int J Mol Sci. 2023;24(21):15622. doi: 10.3390/ijms242115622.
Pătrașcu V, Geoloaica LG, Ciurea RN. Recurrent Idiopathic Sweet Syndrome - Case Report and Literature Review. Curr Health Sci J. 2020;46:90–98. doi: 10.12865/CHSJ.46.01.12.
Dandoy C, Franchimont D, Delvaux C, Buggenhout A, Bernardi D, Del Marmol V, et al. Refractory Pyostomatitis Vegetans With Multiple Aseptic Cutaneous Abscesses Successfully Treated With Filgotinib in Ulcerative Colitis. J Eur Acad Dermatol Venereol. 2025;4:507-9. doi: 10.1002/jvc2.597.
Keiler S, Tyson P, Tamburro J. Metastatic cutaneous Crohn’s disease in children: case report and review of the literature. Pediatr Dermatol. 2009;26(5):604–609. doi: 10.1111/j.1525- 1470.2008.00861.x.
Kurtzman DJB, Jones T, Lian F, Peng LS. Metastatic Crohn’s disease: a review and approach to therapy. J Am Acad Dermatol. 2014;71(4):804-813. doi: 10.1016/j.jaad.2014.04.002.
McKay G, Coromilas A, Liu L, Shaw KS, Murphy M, Punyamurthy N, et al. Interleukin-12/23 and interleukin-23 inhibitors for the treatment of cutaneous Crohn’s disease: a case series from a multi-institutional registry. J Eur Acad Dermatol Venereol. 2025;4(2):458-462. doi: 10.1002/jvc2.615.
Burningham KM, Verma KK, Patel AB, Tyring SK. Resolution of metastatic cutaneous Crohn’s disease with upadacitinib monotherapy. JAAD Case Rep. 2024;46:81-84. doi: 10.1016/j. jdcr.2024.02.017.
Dauria F, Miraglia E, Ramallo CA, Pieretti VM, Bonaura P, Maradeo MR. Enfermedad de Crohn metastásica. Dermatol Argent. 2023;29(3). doi: doi.org/10.47196/da.v29i3.2486.
Frumholtz L, Laurent-Roussel S, Lipsker D, Terrier B. Cutaneous Vasculitis: Review on Diagnosis and Clinicopathologic Correlations. Clin Rev Allergy Immunol. 2021;61(2):181-193. doi: 10.1007/s12016-020-08788-4.
University of Alberta. Sherlock ME, Walsh SRA, Halloran BP, Fedora RN. The DERMATOLOGY of INFLAMMATORY BOWEL DISEASE: A Primer for Gastroenterologists [Internet]. Alberta: Catrile & Associates Ltd; 2011. [citado 10 nov 2025]. Disponible en: https://www.mentoringinibd.com/wp-content/ uploads/2016/09/Dermatology-of-IBD_Primer.pdf?utm_ source=chatgpt.com
Pantic I, Jevtic D, Nordstrom CW, Madrid C, Milovanovic T, Dumic I. Clinical Manifestations of Leukocytoclastic Vasculitis, Treatment, and Outcome in Patients with Ulcerative Colitis: A Systematic Review of the Literature. J Clin Med. 2022;11(3):739. doi: 10.3390/jcm11030739.
Rocha TB, Garate ALSV, Beraldo RF, Lanças SHS, Leite FV, Quera R, et al. Leukocytoclastic Vasculitis as an Extraintestinal Manifestation of Crohn’s Disease. Case Rep Gastroenterol. 2021;15(3):825-831. doi: 10.1159/000519003.
Muñoz-Cedeño RG, Vera-Zapata FR, Ricaurte MC, Rodríguez GN. Leukocytoclastic vasculitis as a rare extraintestinal dermatologic manifestation of inflammatory bowel disease associated with Clostridium difficile: Case report. Rev colomb Gastroenterol. 2021;36(1):12-17. doi: 10.22516/25007440.500.
Chen WT, Chi CC. Association of Hidradenitis Suppurativa With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. JAMA Dermatol. 2019;155(9):1022-1027. doi: 10.1001/jamadermatol.2019.0891.
Martora F, Scalvenzi M, Ruggiero A, Potestio L, Battista T, Megna M. Hidradenitis suppurativa and JAK inhibitors: a review of the published literature. Medicina (Kaunas). 2023;59(4):801. doi: 10.3390/medicina59040801.
Heidari N, Heidari A, Eghbali S, Pishraft-Sabet H, HajikarimHamedani A, Ghane Y, et al. The role of interleukin inhibitors in the treatment of hidradenitis suppurativa: a systematic review of clinical trials. Autoimmun Rev. 2025;24(7):103818. doi: 10.1016/j.autrev.2025.103818.
Bezzio C, Cavalli CAM, Franchellucci G, Dal Buono A, Gabbiadini R, Scalvini D, et al. Psoriasis and inflammatory bowel disease: concomitant IMID or paradoxical therapeutic effect? A scoping review on anti-IL-12/23 and anti-IL-23 antibodies. Therap Adv Gastroenterol. 2024;17:17562848241299564. doi: 10.1177/17562848241299564.
Li R, Lei H, Wang C, Liu X. Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease. Eur J Med Res. 2025;30(1):37. doi: 10.1186/s40001- 025-02295-y. 52. Bucalo A, Rega F, Zangrilli A, Silvestri V, Valentini V, Scafetta G, et al. Paradoxical psoriasis induced by anti-TNFα treatment: evaluation of disease-specific clinical and genetic markers. Int J Mol Sci. 2020;21(21):7873. doi: 10.3390/ijms21217873.
Amatore F, Colombel JF, Delaporte E. Mucocutaneous manifestations of inflammatory bowel disease. Ann Dermatol Venereol. 2024;151(3):103301. doi: 10.1016/j. annder.2024.103301.
Sairenji T, Collins K, Evans D. An Update on Inflammatory Bowel Disease. Prim Care Clin Office Pract. 2017;44(4):673- 692. doi: 10.1016/j.pop.2017.07.010.
Pereira Guedes T, Pedroto I, Lago P. Vedolizumab-associated psoriasis: until where does gut selectivity go? Rev Esp Enferm Dig. 2020;112(7):580-581. doi: 10.17235/reed.2020.6817/2019.
Au M, Heddle G, Young E, Ryan E, Graf S, Tee D, et al. Antitumour necrosis factor-induced skin rashes in inflammatory bowel disease: a systematic review and evidence-based management algorithm. Intern Med J. 2023;53(10):1854–1865. doi:10.1111/imj.15859.
Pagan-Leon S, Werbel T, Montanez-Wiscovich M. Tumor necrosis factor inhibitor-induced eczematous eruption: a report of two cases and review of the literature. Cureus. 2021;13(5):e15078. doi: 10.7759/cureus.15078.
Luzentales-Simpson M, Pang YCF, Zhang A, Sousa JA, Sly LM. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases. Front Cell Dev Biol. 2021;9:612830. doi: 10.3389/ fcell.2021.612830.
Lord JD, Long SA, Shows DM, Thorpe J, Schwedhelm K, Chen J, et al. Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype. Clin Immunol. 2018;193:24-32. doi: 10.1016/j.clim.2018.05.006.
Andres B, Taleban S. Exacerbation of Atopic Dermatitis Associated with Ustekinumab Treatment in Crohn’s Disease. Cureus. 2022;14(9):e29718. doi: 10.7759/cureus.29718.
Olteanu AO, Klimko A, Tieranu I, Orzan OA, Toma CV, Ionescu EM, et al. Paradoxical Psoriasis Induced by Ustekinumab: A Comprehensive Review and Case Report. Medicina (Kaunas). 2024;60(1):106. doi: 10.3390/medicina60010106.
Sedano R, Dhaliwal I, Ramsewak D, Jairath V. Drug-induced Lupus Associated With Vedolizumab in a Patient with Crohn’s Disease. Inflamm Bowel Dis. 2021;27(4):e47-e48. doi: 10.1093/ibd/izaa331.
Malik TA. Inflammatory Bowel Disease: Historical Perspective, Epidemiology, and Risk Factors. Surg Clin North Am. 2015;95(6):1105-22, v. doi: 10.1016/j.suc.2015.07.006.
Yamamoto-Furusho JK, Bosques-Padilla F, Daffra P, De Paula JA, Etchevers J, Galiano MT, et al. Special situations in inflammatory bowel disease: First Latin American consensus of the Pan American Crohn’s and Colitis Organisation (PANCCO) (Second part). Rev Gastroenterol Mex. 2017;82(2):134-155. doi: 10.1016/j.rgmx.2016.07.005.
Bencardino S, Bernardi F, Allocca M, Zilli A, Furfaro F, PeyrinBiroulet L, et al. Advanced Therapies for Inflammatory Bowel Disease and Risk of Skin Cancer: What’s New? Cancers (Basel). 2025;17(10):1710. doi: 10.3390/cancers17101710.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2026 Daniel Barquero-Orias, Ariana Ramirez-Zumbado, Keren Castro-López, Kenneth Ernest-Suárez
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Revista de Gastroenterología del Perú by Sociedad Peruana de Gastroenterología del Perú is licensed under a Licencia Creative Commons Atribución 4.0 Internacional..
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
2022 